We further analyzed the expression of HLA-E, a ligand of NKG2A, in tumors and found that HLA-E was expressed on both tumor cells and immune cells in the tumors of NSCLC patients (Supplementary Figure 2). This evidence concerns the gene HLA-E and neoplasm.